Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer.
Aged
Albumins
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carboplatin
/ therapeutic use
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Female
Humans
Kaplan-Meier Estimate
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Paclitaxel
/ therapeutic use
Treatment Outcome
Non-small-cell lung cancer
carboplatin
nab-paclitaxel
performance status
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
19
01
2019
revised:
02
02
2019
accepted:
06
02
2019
entrez:
8
3
2019
pubmed:
8
3
2019
medline:
12
3
2019
Statut:
ppublish
Résumé
This phase I/II study aimed at assessing the efficacy of combination therapy with carboplatin (CBDCA) on day 1 and nab-paclitaxel (Nab-PTX) on days 1 and 8 of a 21-day cycle in performance status (PS) 2 patients with non-small-cell lung cancer (NSCLC). PS 2 patients with NSCLC were enrolled into a phase I study using a 3 + 3 design. Once the recommended phase II dose (RP2D) was established, the patients were enrolled into phase II. Based on the phase I findings, the RP2D was determined as CBDCA area under the curve 6 mg/ml/min and Nab-PTX 100 mg/m CBDCA plus Nab-PTX therapy is a promising treatment strategy for PS 2 patients with NSCLC.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
This phase I/II study aimed at assessing the efficacy of combination therapy with carboplatin (CBDCA) on day 1 and nab-paclitaxel (Nab-PTX) on days 1 and 8 of a 21-day cycle in performance status (PS) 2 patients with non-small-cell lung cancer (NSCLC).
PATIENTS AND METHODS
METHODS
PS 2 patients with NSCLC were enrolled into a phase I study using a 3 + 3 design. Once the recommended phase II dose (RP2D) was established, the patients were enrolled into phase II.
RESULTS
RESULTS
Based on the phase I findings, the RP2D was determined as CBDCA area under the curve 6 mg/ml/min and Nab-PTX 100 mg/m
CONCLUSION
CONCLUSIONS
CBDCA plus Nab-PTX therapy is a promising treatment strategy for PS 2 patients with NSCLC.
Identifiants
pubmed: 30842183
pii: 39/3/1463
doi: 10.21873/anticanres.13263
doi:
Substances chimiques
130-nm albumin-bound paclitaxel
0
Albumins
0
Carboplatin
BG3F62OND5
Paclitaxel
P88XT4IS4D
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1463-1468Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.